• Azithromycin versus placebo for the treatment of HIV-associated chronic lung disease in children and adolescents (BREATHE trial): study protocol for a randomised controlled trial 

      Gonzalez-Martinez, Carmen; Kranzer, Katharina; McHugh, Grace; Corbett, Elizabeth L.; Mujuru, Hilda A.; Nicol, Mark P; Rowland-Jones, Sarah; Rehman, Andrea M.; Gutteberg, Tore Jarl; Flægstad, Trond; Odland, Jon Øyvind; Ferrand, Rashida (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-12-28)
      Background<br> Human immunodeficiency virus (HIV)-related chronic lung disease (CLD) among children is associated with substantial morbidity, despite antiretroviral therapy. This may be a consequence of repeated respiratory tract infections and/or dysregulated immune activation that accompanies HIV infection. Macrolides have anti-inflammatory and antimicrobial properties, and we hypothesised that ...
    • The effect of azithromycin for management of HIV-associated chronic lung disease on right heart function: Results from the BREATHE trial 

      Majonga, Edith D.; Mapurisa, Gugulethu Newton; Rehman, Andrea M.; McHugh, Grace; Bandason, Tsitsi; Mujuru, Hilda; Gonzalez-Martinez, Carmen; Odland, Jon O.; Kennedy, Neil; Ferrand, Rashida A. (Journal article; Tidsskriftartikkel; Peer reviewed, 2021-11-20)
      Background - Right heart abnormalities and pulmonary hypertension (PH) may be secondary to chronic lung disease. Chronic lung disease is common in children with HIV. In the BREATHE trial (Trial registration: NCT02426112), azithromycin (AZM) reduced the risk of acute respiratory exacerbations in children aged 6–19 years with HIV-associated chronic lung disease (HCLD) taking antiretroviral therapy. ...